Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

NCT01341639 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1250

Enrollment

INDUSTRY

Sponsor class

Conditions

Bacterial Infections
Virus Diseases

Interventions

BIOLOGICAL: V419
BIOLOGICAL: INFANRIX™ hexa
BIOLOGICAL: RotaTeq
BIOLOGICAL: Prevenar 13
BIOLOGICAL: ProQuad™

Sponsor

MCM Vaccines B.V.

Collaborators

[object Object]